Prostate cancer is the most commonly diagnosed cancer in men in the United States and the second-leading cause of cancer death. It also offers a sobering example in the national conversation on racial disparities in cancer care.

In a systematic review and individual patient meta-analysis reported in The Lancet Oncology, Claire L. Vale, PhD, and colleagues in the STOPCAP M1 collaboration identified factors associated and not associated with improved outcomes after the addition of docetaxel to androgen-deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer.

In the phase III NRG Oncology/RTOG 0232 trial reported in the Journal of Clinical Oncology, Jeff M. Michalski, MD, MBA, FASTRO, and colleagues found no significant benefit in 5-year freedom from disease progression with the addition of external-beam radiation therapy to brachytherapy in patients with intermediate-risk prostate cancer.

In an analysis from the phase III VISION trial reported in The Lancet Oncology by Karim Fizazi, MD, PhD, and colleagues, the addition of lutetium (Lu-177) vipivotide tetraxetan to standard of care was associated with improved health-related quality of life in patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.

Black patients may be 1.6 times more likely to believe medical information presented by a Black physician or patient than information presented by a White speaker, according to a new study published by Loeb et al in JAMA Network Open. The findings highlight the importance of increasing racial diversity among health-care providers in order to improve communication with minority patients.